3-氯-5-甲氧基哒嗪 | 123696-02-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-氯-5-甲氧基哒嗪
• 英文名称: 3-chloro-5-methoxy-pyridazine
• 英文别名: 3-Chloro-5-methoxypyridazine
• CAS: 123696-02-6
• 化学式: C₅H₅ClN₂O
• mdl: MFCD08236839
• 分子量: 144.56
• InChiKey: XLGRINRFBNCHQS-UHFFFAOYSA-N

物化性质

• 沸点：
  285 ºC
• 密度：
  1.292
• 闪点：
  126 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  3-氯-5-甲氧基哒嗪 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 4-甲氧基哒嗪
  参考文献：
  名称：

  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy

  摘要：

  Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b]pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.

  DOI：

  10.1021/jm040063i
• 作为产物：
  描述：

  5-methoxy-2-(tetrahydro-2H-pyran-2-yl)-3(2H)-pyridazinone 在 盐酸 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 2.03h， 生成 3-氯-5-甲氧基哒嗪
  参考文献：
  名称：

  3-氯-5-甲氧基哒嗪的大规模合成

  摘要：

  开发了一种大规模合成3-氯-5-甲氧基哒嗪（18摩尔）的方法，该方法依赖于保护4,5-二氯-3（2 H）-哒嗪酮作为四氢吡喃基衍生物2的哒嗪酮氮。用甲醇选择性地保护被保护的哒嗪酮的5-氯位置，得到3，然后4-氯的催化氢化，得到4。用酸去除保护基，然后用三氯氧磷处理，得到目标化合物6，屈服。该途径优于先前描述的该化合物的合成。

  DOI：

  10.1002/jhet.5570320510

文献信息

• Substituted imidazol-pyridazine derivatives
  申请人：——

  公开号：US20030229096A1

  公开（公告）日：2003-12-11

  The present invention relates to compounds of formula 1 wherein A is an unsubstituted or substituted cyclic group; and R is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof. These compounds are NMDA NR-2B receptor subtype specific blockers and are useful in the treatment of neurodegeneration, depression and pain.

  本发明涉及以下式的化合物 1 其中A是未取代或取代的环状基团；以及 R是氢或较低的烷基； 或其药学上可接受的酸盐。这些化合物是NMDA NR-2B受体亚型特异性阻断剂，对于治疗神经退行性疾病、抑郁症和疼痛具有用处。
• 3-pyrazolyloxypyridazines, herbicidal compositions and uses thereof
  申请人：Monsanto Company

  公开号：US05536701A1

  公开（公告）日：1996-07-16

  Disclosed are certain 3-pyrazolyloxypyridazines, compositions thereof which are herbicidal and methods of using such composition for controlling undesired plants. Also disclosed are mixtures of such pyridazines and acetanilide herbicides, to which mixture a safener may be added, if desired. Intermediate compounds useful in preparing the pyrazolyloxypyridazines are also disclosed.

  公开了某些3-吡唑氧基哒嗪化合物，以及它们的组合物，这些组合物具有除草活性，以及使用这些组合物控制有害植物的方法。还公开了这些哒嗪与乙酰苯胺类除草剂的混合物，如果需要，可以向这种混合物中添加一个安全剂。还披露了用于制备吡唑氧基哒嗪的中间化合物。
• [EN] HETEROARYLBENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLBENZIMIDAZOLE
  申请人：BAYER PHARMA AG

  公开号：WO2017102091A1

  公开（公告）日：2017-06-22

  The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式（I）中的杂环芳基苯并咪唑化合物，其中R1、R2、R3、R4和R5如本文所定义，制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或炎症性疾病的药物组合物，作为唯一活性成分或与其他活性成分组合使用。
• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• [EN] ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS<br/>[FR] INHIBITEURS DE RÉCEPTEURS ERBB UTILISÉS COMME AGENTS ANTITUMORAUX
  申请人：SUZHOU ZANRONG PHARMA LTD

  公开号：WO2021179274A1

  公开（公告）日：2021-09-16

  Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

  本文提供了作为I型受体酪氨酸激酶抑制剂的新化合物，包括其中一种或多种化合物及其盐作为活性成分的药物组合物，以及在哺乳动物，尤其是人类中治疗高增殖性疾病（如癌症和炎症）中使用这些化合物及其盐的用途。